BREAKING: Tern Therapeutics has announced its launch and entered into a global licensing agreement with REGENXBIO for RGX-381 and RGX-181 (now designated TTX-381 and 181, respectively) to form its initial therapeutic pipeline. TTX-381 and TTX-181 are novel one-time gene therapy products being developed for CLN2 Batten disease. Read Tern’s full press release, which includes statements from BDSRA’s Dr. Ineka Whiteman, and REGENXBIO’s letter to the Batten community.

Tern: https://bdsrafoundation.org/.../TTX-Press-Release-2024.08...

REGENXBIO: https://bdsrafoundation.org/.../CLN2-community-letter...

The REGENXBIO RGX-181 and RGX-381 programs have been outlicensed to Tern Therapeutics, a new biotech founded by the team that led these programs at REGENXBIO. The programs will take some time to resume, and the Tern team is working diligently to accomplish this. Here’s our Head of Research & Medical Affairs Dr. Ineka Whiteman with more.